Amazon and National Safety Council Create First-of-its-Kind Partnership to Solve the Most Common Workplace Injury in the U.S.
10.6.2021 15:00:00 EEST | Business Wire | Press release
Today Amazon (NASDAQ:AMZN) and National Safety Council (NSC) announced a five-year partnership to invent new ways to prevent the largest category of workplace injuries in the U.S., musculoskeletal disorders (MSDs). Amazon and NSC have been working together for months on this first-of-its-kind collaboration.
“Through this partnership we’ll be able to solve problems that people face every day so they can live their fullest lives,” said Lorraine Martin, president and CEO of National Safety Council. “Going to work should be a positive, rewarding, and safe experience. We are grateful for the generous support of Amazon to help companies around the world solve this important issue while fueling our nonprofit mission to keep employees safe in the workplace.”
"As a member of Amazon’s onsite safety team, my goal is to do everything I can to keep my fellow employees healthy at work so we all go home safe to our friends and families," said Chelsea Weimer, an hourly employee at Amazon’s fulfillment center in Baltimore, MD. "Amazon has a high standard for safety; this partnership is more proof of that and I can't wait to see the work that's done to help decrease MSDs."
The partnership will aim to prevent MSDs across a variety of industries by engaging key stakeholders, conducting research, inventing new technology and processes, and scaling the results. The collaboration is made possible by Amazon’s $12 million contribution, the largest corporate contribution in the history of NSC, and will include five key components:
Advisory Council: Establishing an international advisory council to bring together safety experts, corporations, and researchers in public and private sectors. The advisory council will work together to review the most promising approaches to MSD prevention, shape the development of partnership components, and engage external parties on MSD prevention.
Pioneering Research: Conducting research utilizing next-generation artificial intelligence, natural language processing, and machine learning tools to explore current and future MSD innovations and trends. The research will be available to all industries to explore and glean insights.
Small Business and University Grants: Providing grants to small businesses, universities, and university students. These grants will fund research and innovation that help companies of all sizes achieve impact.
Innovation Challenge: Incubating and fostering innovative and practical solutions to address MSDs through Innovation Challenge competitions. These competitions will bring together experts to collaborate, iterate, and share techniques and ideas.
Industry Call to Action – The MSD Pledge: Amazon and NSC will share solutions discovered throughout the partnership to inspire change through the creation of The MSD Pledge and a call on other companies to also join the effort to:
- Track proactive indicators of injuries to ensure proper risk mitigation and implement prevention strategies based on data.
- Implement an MSD prevention program that includes educating employees and employers about injury prevention.
- Embrace and drive forward innovative solutions to prevent MSDs and share best practices with other organizations worldwide.
The partnership kicks off in June during National Safety Month and in its first year will focus on launching the advisory council, identifying research partners, analyzing existing data, and developing the grant and Innovation Challenge programs.
“Nothing is more important than the safety of our employees, and this partnership will allow us to dive deep into the best way to reduce MSDs,” said Heather MacDougall, Amazon’s vice president of worldwide workplace health and safety. “National Safety Council has a long history of advancing safe practices in the workplace, and we look forward to working alongside them as well as many other businesses, experts, and students around the world to innovate and solve for this important issue.”
The NSC collaboration is another step in Amazon’s long-term mission to be Earth’s Safest Place to Work, which includes an investment of over $300 million into safety projects in 2021, and a goal to cut its recordable incident rate by 50% by 2025. Every day, Amazon works closely with health and safety experts, conducts thousands of safety inspections inside every building, and actively seeks employee feedback on how to improve their well-being at work. To see inside Amazon’s workplace and learn more about its team and technology, sign up for a fulfillment center tour at www.amazon.com/FCtours.
National Safety Council is America’s leading nonprofit safety advocate—and has been for over 100 years. As a mission-based organization, it works to eliminate the leading causes of preventable death and injury, focusing its efforts on the workplace, roadway, and impairment. It creates a culture of safety to keep people safer not only at work, but also beyond the workplace.
To learn more about employee safety at Amazon, visit www.amazon.com/employee-safety.
To learn more about the partnership, visit www.nsc.org/amazonpartnership.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005214/en/
Contact information
Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
